Long-term efficacy and safety of a repeat treatment course of rituximab in ra patients with an inadequate response to disease-modifying antirheumatic drugs

被引：0
|
作者：
Emery, P.
Bykerk, V. P.
Ferraccioli, G.
Udell, J.
van Vollenhoven, R. F.
Rowe, K.
Agarwal, S.
Shaw, T.
机构：
[1] Gen Infirm, Dept Rheumatol, Leeds LS1 3EX, W Yorkshire, England
[2] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[3] Univ Cattolica Sacro Cuore, Div Rheumatol, Rome, Italy
[4] Arthritis Grp, Philadelphia, PA USA
[5] Karolinska Univ Hosp, Dept Rheumatol, Stockholm, Sweden
[6] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[7] Genentech Inc, San Francisco, CA 94080 USA
来源：
JOURNAL OF RHEUMATOLOGY | 2007年 / 34卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1611 / 1612
页数：2
相关论文
共 50 条
  • [1] Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    Van Vollenhoven, R. F.
    Rowe, K.
    Agarwa, S.
    Shaw, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 58 - 58
  • [2] Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs.
    Emery, P.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    van Vollenhoven, R. F.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S228 - S228
  • [3] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    van Vollenhoven, R. F.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 40 - 41
  • [4] Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
    Charles-Schoeman, Christina
    Burmester, Gerd
    Nash, Peter
    Zerbini, Cristiano A. F.
    Soma, Koshika
    Kwok, Kenneth
    Hendrikx, Thijs
    Bananis, Eustratios
    Fleischmann, Roy
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (07) : 1293 - 1301
  • [5] Sustained efficacy of repeat treatment courses of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    van Vollenhoven, R. F.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 430 - 430
  • [6] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
    Choy, Ernest
    Freemantle, Nick
    Proudfoot, Clare
    Chen, Chieh-I
    Pollissard, Laurence
    Kuznik, Andreas
    van Hoogstraten, Hubert
    Mangan, Erin
    Carita, Paulo
    Thi-Minh-Thao Huynh
    [J]. ADVANCES IN THERAPY, 2019, 36 (04) : 817 - 827
  • [7] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
    Ernest Choy
    Nick Freemantle
    Clare Proudfoot
    Chieh-I Chen
    Laurence Pollissard
    Andreas Kuznik
    Hubert van Hoogstraten
    Erin Mangan
    Paulo Carita
    Thi-Minh-Thao Huynh
    [J]. Advances in Therapy, 2019, 36 : 817 - 827
  • [8] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors
    Keystone, E.
    Pope, J. E.
    Fleischmann, R.
    Emery, P.
    Chubick, A.
    Dougados, M.
    Baldassare, A. R.
    Bathon, J. M.
    Hessey, E.
    Totoritis, M.
    Cooper, S.
    [J]. JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1617 - 1618
  • [9] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors
    Keystone, E.
    Fleischmann, R.
    Emery, P.
    Chubick, A.
    Dougados, M.
    Baldassares, A. R.
    Bathon, J. M.
    Hessey, E.
    Totoritis, M.
    Cooper, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 323 - 324
  • [10] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors.
    Keystone, E.
    Fleischmann, R. M.
    Emery, P.
    Chubick, A.
    Dougados, M.
    Baldassare, A. R.
    Bathon, J. M.
    Hessey, E.
    Totoritis, M.
    Cooper, S.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S328 - S328
12345